Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10 Genitourinary 9 Gynecologic 5 Breast 2 Thoracic 1 Other hematologic neoplasm 1 NET 1 Head & Neck 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 8 Specimen Handling 5 Magnetic Resonance Spectroscopy 5 pembrolizumab 3 Everolimus 3 cabozantinib 2 X-Rays 2 repotrectinib 1 peposertib 1 pazopanib 1 olaparib 1 lenvatinib 1 fludarabine 1 entrectinib 1 belinostat 1 aldesleukin 1 Watchful Waiting 1 Tomography, X-Ray Computed 1 Tomography, Emission-Computed, Single-Photon 1 Sunitinib 1 Single Photon Emission Computed Tomography Computed Tomography 1 Salts 1 Positron Emission Tomography Computed Tomography 1 Photons 1 Phantoms, Imaging 1 PT-100 dipeptide 1 Octreotide 1 Nivolumab 1 Lutetium-177 1 Lutetium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

lenvatinib × NET × 30 days × Clear all

NCT04848337 2026-05-11

PLANE-PC

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting

45 enrolled 8 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡